Search for: rheumatoid arthritis methotrexate autoimmune disease biomarker gene expression GWAS HLA genes non-HLA genes
| ID | PMID | Title | PublicationDate | abstract |
|---|---|---|---|---|
| 3349944 | [Long-term course of chronic polyarthritis under basic drug therapy]. | 1988 Mar 25 | A retrospective analysis was undertaken of 31 patients with classical or proven chronic rheumatoid arthritis (CRA) who had been on a regimen of basic medication (gold salts, D-penicillamine, chloroquine, azathioprine--alone or in combination). Disease activity was checked by clinical, biochemical, immunological and radiological criteria. The laboratory results could not be altered by the basal medication and there was no relationship with the clinical and radiological findings, except for immunological results. None the less, the clinical symptoms improved under basal medication, even though the functional index got worse. The degree of joint destruction at the beginning and end of the observation period was markedly higher for seropositive than sero-negative cases, without significant differences in the rate of progression of joint destruction. Thus, definite long-term remission was achieved regarding the inflammatory changes but not the progressing joint destruction. | |
| 1877856 | Distribution of type VI collagen expression in synovial tissue and cultured synoviocytes: | 1991 Jul | Type VI collagen has recently been shown to be an important component of connective tissue. Double label immunofluorescence procedures were used to immunolocalize type VI collagen in normal and rheumatoid synovium and its distribution was compared with that of fibronectin. In normal synovium type VI collagen is expressed in the synovial membrane but not in the interstitium of the villus. In rheumatoid synovium, however, type VI collagen is extensively deposited in both the interstitial connective tissue and along the lining of the synovial membrane. Cultured rheumatoid and normal synoviocytes produce type VI collagen and fibronectin and incorporate them into their extracellular matrix. These data suggest that type VI collagen may play a part in matrix remodelling of the inflamed joint. | |
| 3060612 | Ketoprofen versus indomethacin in patients with rheumatoid arthritis: a multicenter double | 1988 Oct | Oral ketoprofen (200-300 mg/day) and indomethacin (100-150 mg/day) were compared in a 12-week double blind study involving 140 patients with rheumatoid arthritis. The treatments were generally equally effective in most assessments, producing highly significant (p less than 0.01) improvements from baseline values within one week. Only isolated statistically significant differences (p less than 0.05) were detected between the 2 treatments: ketoprofen had a more pronounced effect than indomethacin in functional class (Weeks 1 and 12), swollen joint score (Week 1), and patients' global assessments (Week 12); indomethacin was significantly superior in improving grip strength at Week 4. The clinical significance of these statistically established differences may be questioned. The incidence of side effects, primarily gastrointestinal and neurologic, was also comparable in the 2 treatments. | |
| 3291480 | [The temporomandibular joint from the rheumatologic viewpoint]. | 1988 Mar | Temporomandibular joint affections in rheumatic disease are described. They were seen in inflamed joint diseases, mostly in rheumatoid arthritis, and less so in juvenile rheumatoid arthritis, psoriatic arthritis, Reiter's syndrome, ankylosing spondylitis, and collagen vascular disease. In osteoarthrosis, the temporomandibular joint affection occurs frequently but pain seems to occur most infrequently. We must bear in mind that a painful temporomandibular joint could be a symptom of myalgia, especially fibrositis syndrome with its painful tendon. | |
| 2265892 | Psychoimmunology and rheumatoid arthritis: concepts and methodologies. | 1990 | The recent growth of knowledge about the immune-neuroendocrine network has important implications for future research into psychosomatic hypotheses about the aetiology of rheumatoid arthritis. The available evidence suggests that three phases of the aetiological process in rheumatoid arthritis need to be considered separately because of the different role that psychological and social variables may play at different points of the disease. These are the loss of immunological tolerance, the onset of joint inflammation and the long-term disease course. It is suggested that future studies will need to be prospective, include multiple sampling techniques and comparisons within patient groups if they are to elucidate the precise role of psychoneuroimmunological factors in rheumatoid arthritis. | |
| 3358171 | Brooks fusion for atlantoaxial instability in rheumatoid arthritis. | 1988 Apr | Atlantoaxial instability in rheumatoid arthritis has been recognized in the natural history of rheumatoid arthritis, but successful surgical stabilization has proven to be elusive. We review our experience using the Brooks technique of wedge compression arthrodesis combined with halo immobilization in five women with rheumatoid arthritis with symptomatic C1-2 subluxation. Halo-vest immobilization was continued for six weeks postoperatively, and then exchanged for a rigid cervical orthosis for an additional six weeks. Solid, asymptomatic fusion developed in all patients within this 12-week period. Follow-up ranges from 18 to 56 months. One major complication occurred in a patient who had significant postoperative quadriparesis in spite of normal intraoperative sensory evoked potentials; it has since slowly resolved. | |
| 1856803 | Methotrexate in rheumatoid arthritis: effects on disease activity in a multicenter prospec | 1991 Mar | One hundred and twenty-three patients with rheumatoid arthritis (RA) who successfully completed a randomized trial comparing oral methotrexate (MTX) to auranofin enrolled in a longterm prospective study of oral MTX. Of the 91 patients who completed 24 months of therapy, a significant (p = 0.0001) improvement was noted compared to baseline in all clinical disease variables and the Westergren erythrocyte sedimentation rate (ESR). Marked improvement occurred in 94 (76%) and 98 (80%) of the patients in the joint pain/tenderness index and joint swelling index at the last evaluable visit (mean 26 months). Of the 77 patients with an elevated ESR at baseline, 29 (38%) patients normalized it (less than 20 mm/h) while receiving therapy (p less than 0.01). A significant reduction in prednisone dose was also seen. Adverse events occurred frequently but were generally mild in severity. Twenty-seven patients (22%) withdrew during the study. Four (3%) withdrew due to lack of efficacy, and 6 (5%) because of adverse experiences. The overall probability of continuing therapy in the study for 48 months was projected at 72%. This large prospective study supports the observation of earlier smaller studies that MTX is an effective drug in the treatment of RA. | |
| 3813674 | Uptake of chloroquine and hydroxychloroquine by human blood leucocytes in vitro: relation | 1987 Jan | The accumulation of chloroquine and hydroxychloroquine in unfractionated mononuclear cells and in purified monocytes, lymphocytes, and neutrophil polymorphonuclear leucocytes (PMN) was measured in vitro. Accumulation of both drugs in leucocytes was time and dose dependent. Cellular levels comparable to those found during antirheumatic therapy were achieved by preincubation for 60 minutes with up to 0.1 mM chloroquine or hydroxychloroquine. | |
| 1696993 | CD5+ B lymphocytes in systemic lupus erythematosus and rheumatoid arthritis. | 1990 Jun | B lymphocytes which express the CD5 antigen on their cell surface have the ability to produce autoantibodies in vitro. We describe 2 patients, one with systemic lupus erythematosus and another with rheumatoid arthritis, whose percentages of peripheral blood CD5+ B lymphocytes were dramatically increased to 68 and 100%, respectively. A reduction of this subpopulation of B cells was associated with clinical improvement after therapy. This association suggests a relationship between CD5+ B cells and autoimmune disease activity. | |
| 3382450 | Antibodies against native type II collagen do not precede the clinical onset of rheumatoid | 1988 Jun | Serum levels of IgG and IgM antibodies to native human type II collagen were determined in 22 pre-illness sera from subjects who developed seropositive rheumatoid arthritis (RA) 4 months to 5 years after sera were obtained, in 51 specimens from 35 healthy controls, and in 4-5 specimens from 58 patients with recent-onset RA. The antibody levels in all pre-illness serum specimens fell within the range seen for the healthy controls. Four RA patients had an IgG class antibody level and 4 had an IgM class antibody level that was above the highest level observed for controls, in at least 1 serum sample. No significant difference in the mean level of anticollagen antibodies was observed in the followup specimens from RA patients. | |
| 3330696 | Are major histocompatibility system class III products independent markers for susceptibil | 1986 Jun | Three components of the complement pathway C2, Factor B, and C4 are coded for by four genes C2, Bf, C4A, and C4B in the class III region of the major histocompatibility system in man. Studies of the polymorphism of these plasma proteins have shown associations of BfS, C2C, and C4B3 (2.9) with RA. Family studies have shown that these markers occur together, usually on DR4 positive haplotypes and in particular on the A2-Cw3-Bw62-C4B3-C4A3-BfS-C2C-DR4 haplotype. It is argued that Class III gene products are unlikely to be independent markers of susceptibility to RA. | |
| 1936347 | [The effect of ultrasonic therapy in rheumatoid arthritis of the temporomandibular joint]. | 1991 Aug | The mouth opening distance, the joint pressure sensitiveness and the biting strength have been measured. In the treated group all three examined parameters showed significant improvement while in the placebo group two parameters (pressure sensitiveness and mouth opening distance) changed significantly. The placebo effect collateral to the real therapeutic effect is not a rare phenomenon in physico-therapy. However, the real effect of the physico-therapeutic treatment can be judged only by means of double blind examination. | |
| 1768158 | Exacerbation of rheumatoid arthritis in patients treated with methotrexate after administr | 1991 Dec | A double blind, placebo controlled trial examined the effects of folinic acid on the efficacy and toxicity of methotrexate in 27 patients with rheumatoid arthritis. Clinical and laboratory indices of disease activity worsened significantly in the 13 patients treated with folinic acid after four weeks of treatment, but not in the 14 patients treated with placebo. Exacerbation of rheumatoid arthritis led to withdrawal of the test drug in seven of the patients treated with folinic acid but in none of those treated with placebo. It is concluded that excerbation of rheumatoid arthritis is likely when folinic acid is given shortly after the weekly dose of methotrexate. | |
| 2118434 | Soluble interleukin-2 receptor and soluble CD8 antigen in active rheumatoid arthritis. | 1990 Oct | Concentrations of soluble interleukin-2 receptor (sIL-2R) and of soluble CD8 antigen (sCD8) in sera and in supernatants of phytohemagglutinin (PHA)-stimulated peripheral blood mononuclear cells (PBMC) derived from patients with active rheumatoid arthritis (RA) were studied. sIL-2R concentrations in sera derived from patients with RA (1484 +/- 382 U/ml) were significantly higher than in sera derived from healthy controls (380 +/- 110 U/ml; P less than 0.0005). In contrast, supernatants of PHA-stimulated PBMC derived from patients with RA contained similar amounts of sIL-2R (727 +/- 467 U/ml) as those derived from healthy control individuals (833 +/- 508 U/ml; P greater than 0.1). When investigated for the presence of sCD8 antigen, sera derived from patients with RA contained significantly lower amounts (30 +/- 28 U/ml) than sera derived from healthy controls (405 +/- 136 U/ml; P less than 0.0005). Similarly, PHA stimulation of PBMC derived from patients with RA resulted in a significantly lower production of sCD8 (35 +/- 46 U/ml) as compared to the one obtained by PHA stimulation of PBMC derived from healthy controls (177 +/- 59 U/ml; P less than 0.0005). This difference could not be explained by a lower proliferative response to PHA by PBMC derived from patients with RA (21,474 +/- 14,022 cpm) as compared to healthy controls (29,549 +/- 11,188 cpm; P greater than 0.05). Our data demonstrate that PBMC derived from patients with active RA differ from PBMC derived from healthy individuals concerning their ability to produce sIL-2R and sCD8. | |
| 2774695 | Effects of low dose corticosteroids on bone mass in rheumatoid arthritis: a longitudinal s | 1989 Jul | Low dose corticosteroids are effective in suppressing synovitis in rheumatoid arthritis (RA), but there remains concern about their side effects, particularly osteoporosis. To examine the effects of low dose corticosteroids on bone loss in RA bone mineral density (BMD) was measured in the lumbar spine and hip for up to two years in 15 patients treated with these agents (mean dose prednis(ol)one 6.6 mg/day). 15 patients not receiving them, and 15 age matched controls. The initial BMD at both skeletal sites was significantly reduced in both patient groups compared with controls. The mean change in bone density was 0.2, 0.1, and -0.1% a year in the spine and -2.0, -1.9, and -1.0% a year in the hip respectively for the three groups. These rates of bone loss were not significantly different between groups at either site. These findings suggest that low dose corticosteroid treatment in RA is not associated with an increased risk of osteoporosis. | |
| 3283356 | Comparison of three pulse methylprednisolone regimens in the treatment of rheumatoid arthr | 1988 Feb | Twenty-nine patients with active rheumatoid arthritis entered a 6-week, parallel, randomized, double blind trial, comparing 1000 mg IV-methylprednisolone (MP), 320 mg IV-MP and 320 mg IM-MP. Although clinical benefit was noted in all groups, there were no differences among groups for duration of benefit (days: 1000 mg IV: 23.4; 320 mg IM: 17.2; 320 mg IV: 21.9) (p = 0.72), patient global scale (p = 0.57), or MD global scale (p = 0.36). Power to tell a 33% difference among groups for joint tenderness and patient global scale was 0.64 and 0.78. No serious drug related toxicity occurred. This preliminary study in a small patient group suggests that no large differences (33%) can be discerned among these 3 regimens. However, a larger study is indicated to reduce possible beta errors. | |
| 3479115 | Remission of rheumatoid arthritis with the successful treatment of acute myelogenous leuke | 1987 Oct | We describe 2 patients in whom a sustained remission of longstanding rheumatoid arthritis occurred with treatment for acute myelogenous leukemia (cytosine arabinoside, daunorubicin, and m-AMSA), even though both illnesses had been refractory to therapy with standard disease-modifying agents. These 2 patients represent the first successful treatment of rheumatoid disease using such an approach. | |
| 3035353 | Low prevalences of coronary heart disease (CHD), psoriasis, asthma and rheumatoid arthriti | 1987 Apr | The low prevalences of CHD, psoriasis, asthma and rheumatoid arthritis in Eskimos have been attribute to the high dietary intake of EPA from fish and marine mammals. However, even on a Western diet, Eskimos have plasma arachidonic acid (AA) levels far below those seen in Europeans while dihomogammalinolenic acid (DGLA) levels are higher in Eskimos. These low AA and high DGLA levels seem to be due to a genetic abnormality in EFA desaturation since they are found even when EPA intakes are low. Since AA is known to be important in the pathogenesis of CHD, asthma, psoriasis and arthritis, while DGLA has properties which make it of likely therapeutic value in these conditions, the genetically high DGLA and low AA are likely to be as important as dietary EPA in determining Eskimo disease patterns. | |
| 2060157 | Synovial cell secretion of IL-2 in vitro, a limiting dilution analysis. | 1991 Mar | Limiting dilution analysis (LDA) was used to analyze the defect of production of IL-2 by synovial fluid cells in rheumatoid arthritis (RA). LDA is a relatively simple means of separating T-cell function from the potential effects of accessory-cells, suppressor factors and adsorption. The number of precursor cells for interleukin-2 (IL-2) secretion was determined among peripheral blood cells (PBL) from healthy control individuals, and in PBL and synovial fluid (SF) mononuclear cells from patients with rheumatoid arthritis (RA). Although the frequency of such cells in the PBL of the controls and RA patients was similar, that of the SF was significantly lower (about one sixth). This difference could not be accounted for by an inability of the SF cells to proliferate in culture, by the presence of suppressor cells, by absorption of IL-2, or by a relative lack of accessory-cell function in the SF fraction. Culturing synovial cells without stimulant for three days resulted in a two- to three-fold increase in the apparent frequency of secreting cells, but the same proportional increase followed similar manipulation of peripheral blood cells. Pre-incubation of normal lymphocytes in RA synovial fluid did not result in suppression of their ability to secrete IL-2. We conclude that the poor secretion of IL-2 after mitogen stimulation of SF cells is an intrinsic property of the T-cell, and not due to the presence of other factors. There was no evidence that this defect was selectively reversible by "resting" the cells prior to culture. | |
| 3310925 | Nonathymulin in rheumatoid arthritis: two double blind, placebo controlled trials. | 1987 Jul | Two randomised double blind, placebo controlled trials have been carried out to assess the effectiveness of nonathymulin, a synthetic thymic peptide hormone, in the treatment of rheumatoid arthritis (RA) and to compare three different dosage schedules (1, 5, and 10 mg/day). Nonathymulin 5 mg proved to be the most efficient dose, providing significant clinical improvement as evaluated by the global assessment of all patients who entered the trials (56% v 17% in the placebo group) (p less than 0.02) and by four objective parameters. This effect was accompanied with minimal adverse effects and was not associated with clear changes in immunological parameters. A significant correlation was observed, however, in clinical response to nonathymulin, and T cell subset imbalance was assessed using monoclonal anti-T cell antibodies and a functional suppressor T cell assay. |